Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments

Epidemiology Biostatistics and Public Health

Volumn 12, Issue 3, 2015, Pages

  Scalone, Luciana ^a,b   Cortesi, Paolo Angelo ^a,b   Ciampichini, Roberta ^a,b   Cesana, Giancarlo ^a   Mantovani, Lorenzo Giovanni ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b CHARTA Foundation   (Italy)

Author keywords

EQ 5D 3L; EQ 5D 5L; Health related quality of life; Norms; Utility

Indexed keywords

EID: 84942163822     PISSN: None     EISSN: 22820930     Source Type: Journal    
DOI: 10.2427/11457     Document Type: Article

References (50)

1. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992; 305: 1074-1077
2. Wilson IB, Cleary PD. Linking clinical variables with health related quality of life: A conceptual model of patient outcomes. JAMA, 1995; 273: 59-65
3. Coast J, Bailey C, Orlando R et al. "The icecap-scm tells you more about what i'm going through"-measuring the quality of life amongst patients receiving supportive and palliative care. BMJ Support Palliat Care, 2015; 5(1):110-111.
4. Kress MA, Jensen RE, Tsai HT, Lobo T, Satinsky A, Potosky AL. Radiation therapy at the end of life: a population-based study examining palliative treatment intensity. Radiat Oncol. 2015, 13;10(1):15
5. Färkkilä N, Torvinen S, Roine RP, et al. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. Qual Life Res. 2014; 23(4):1387-1394.
6. Kim KU. Measurement of quality of life in patients with end-stage cancer. Cancer Nurs. 2014; 37(1):44-49
7. Scalone L, Mantovani LG, Krol M et al. Costs, quality of life, treatment satisfaction and compliance in patients with ß-thalassemia major undergoing iron chelation therapy: the ITHACA study. Current Medical Research and Opinion, 2008; 24(7):1905-1917
8. Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013; 19(5):736-743.
9. Scalone L. Investing in hemophilia care: benefits and costs for patients and society. Seminars in Hematology, 2008; 45: S31-S34
10. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia, 2006; 12: 154-162
11. Cortesi PA, Scalone L, D'Angiolella L et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S126-S131
12. Gualtierotti R, Scalone L, Ingegnoli F et al. Health related quality of life assessment in patients with systemic sclerosis. Reumatismo, 2010; 62(3):210-214
13. Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology, 2008; 47(11):1664-1670.
14. Cortesi PA, Scalone L, Angelini G, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis, 2013; 70(3):158-168
15. Scalone L, de Portu S, Casati A, et al. Quality of life of adult patients with atopic dermatitis: the coda study [abstract]. Value in Health, 2006; 9(6); A269
16. Scalone L, Gelmetti C, de Portu S, et al. Quality of life of paediatric patients with atopic eczema and their families [abstract]. Value in Health, 2005; 8(6); A148.
17. Di Stasi F, Mantovani LG. Quality of Life of Gastroesophagel Reflux Disease Patients [Abstract]. Value in Health, 2004; 7(6): 641
18. Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open gastroenterology, 2015; IN PRESS
19. Cortesi PA, Mencacci C, Luigi F, et al. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry. 2013; 13(98): 2-16
20. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life in hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 2003; 102: 2358-2363
21. Zucco F, Ciampichini R, Lavano A, et al. Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study. Neuromodulation, 2015, 18(4):266-76
22. Cortesi PA, Ciaccio A, Rota A, et al. Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. Journal of Viral Hepatitis, 2015; 22: 175-183
23. National Institute of Health and Care Excellence (NICE) (formerly the National Institute of Health and Clinical Excellence). NICE Guide to the Methods of Technology Appraisal. London: NICE; 2013.
24. Ministero della Salute. Piano Nazionale di Prevenzione Vaccinale. http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf. Accessed in March 2015.
25. Health technology assessment. I quaderni di monitor 2009. 4°supplemento n. 23 AIES. Proposta di Linee Guida per la valutazione economia degli interventi sanitari. Politiche Sanitarie 2009; 10: 91-99.
26. Regione Lombardia-DGR n. VIII / 7856 of 30.07.2008-Determinazione in merito alla valutazione dell'appropriatezza d'uso di farmaci, dispositivi biomedici e tecnologie diagnostico-terapeutiche al fine del loro impiego nell'ambito del Servizio Sanitario Regionale secondo gli indirizzi del PSSR e determinazioni conseguenti
27. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the italian group of pharmacoeconomic studies. Drug Information Journal 2001; 35:189-201.
28. Golicki D, Niewada M. General population reference values for 3 level EQ-5D (EQ-5D-3L) questionnaire in Poland. Polskie Archiwum Medycyny Wewnętrznej, 2015; 125 (1-2): 18-26
29. Clemens S, Begum N, Harper C, Whitty JA, Scuffham PA. A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res. 2014; 23(8):2375-2381
30. Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Brahler E. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Quality of Life Research, 2014; 23: 443-447
31. Szende A, Janssen B, Cabasés J. Self-Reported Population Health. An International perspective based on EQ-5D. Springer Open, 2014
32. Mantovani LG, Scalone L, Perelli Cippo P, et al. Quality of life of Italian general population aged 40 to 79 years old [abstract]. Value in Health, 2005; 8(6): A53
33. König HH, Bernert S, Angermeyer MC, et al. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire. Med Care. 2009;47(2): 255-261
34. Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10): 1727-1736 DEMO ISTAT: http://demo.istat.it/pop2012/index.html
35. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33(5): 337-343
36. Herdman M, Fox-Rushby J, Rabin R, Badia X, Selai C. Producing other language versions of the EQ-5D. In: Brooks R., Rabin R., de Charro F. (eds). The measurement and valuation of health status using EQ-5D: A European perspective. Kluwer Academic Publishers, 2003
37. Scalone L, Ciampichini R, Fagiuoli S, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res. 2013; 22(7):1707-1716
38. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013; 22(7):1717-1727
39. van Hout B, Janssen MF, Feng YS, et al. Value sets for the EQ-5D-5L: A mapping approach. Value in Health, 2012; 15(5):708-715
40. Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Quality of Life Research, 2010; 19(6): 875-886
41. Ravens Sieberer U, Wille N, Badia X, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life Research, 2010; 19(6): 887-897
42. Scalone L, Tomasetto C, Matteucci MC, Selleri P, Broccoli S, Pacelli B, Cavrini G. Assessing Quality of Life in Children and Adolescents: Development and Validation of the Italian Version of the EQ-5D-Y. Italian Journal of Public Health, 2011; 8 (4): 331-341
43. Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value in Health, 2013; 16(5): 814-822
44. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health, 2008; 11(2):275-284
45. Governo Italiano, dipartimento per l'informazione e l'editoria. Survey untitled "Se votassimo noi, il 51% direbbe sì all' Ue", conducted in June 2015 by IPSOS and commissioned by Corriere della Sera. Available from: http://www.sondaggipoliticoelettorali.it/ListaSondaggi. aspx?st=SONDAGGI [Accessed September 1, 2015]
46. Scalone L, Cesana GC, Furneri G; et al. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases. PLOS One 2014: e113741.
47. Blasi F, Cesana G, Conti S, et al. The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. PLoS ONE 2014; 9 (6): e101228
48. Madotto F, Fornari C, Chiodini V et al. Utilization, Outcomes and Costs of Implantable Cardioverter Defibrillators in Italy: A Population-Based Analysis Using Healthcare Administrative Databases. Global Journal of Epidemiology and Public Health. 2014;1: 48-56
49. Madotto F, Riva MA, Fornari C, et al. Administrative databases as a tool for identifying healthcare demand and costs in an over-one million population. Epidemiology, Biostatistics and Public Health. 2013; 10(2): 1-11.
50. Mantovani LG, Fornari C, Madotto F, et al. Burden of Acute Myocardial Infarction. Int J Cardiol 2011; 150(1):111-112